Crinetics Pharmaceuticals (CRNX) Accumulated Depreciation (2017 - 2025)

Crinetics Pharmaceuticals' Accumulated Depreciation history runs 9 years deep, the most recent figure standing at $9.6 million for Q2 2025.

• In Q2 2025, Accumulated Depreciation rose 53.84% year-over-year to $9.6 million; the TTM figure through Jun 2025 stood at $9.6 million (up 53.84% YoY), while the FY2024 annual figure was $7.7 million, up 52.57% from the prior year.
• Accumulated Depreciation was $9.6 million for Q2 2025 at Crinetics Pharmaceuticals, up from $8.6 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $9.6 million in Q2 2025 to a low of $3.0 million in Q1 2021.
• Historically, Accumulated Depreciation has averaged $5.2 million across 5 years, with a median of $4.6 million in 2023.
• The sharpest annual moves came in 2021 and 2023: Accumulated Depreciation jumped 62.02% in 2021, then grew 16.95% in 2023.
• A 5-year view of Accumulated Depreciation shows it stood at $3.5 million in 2021, then gained by 17.36% to $4.1 million in 2022, then climbed by 24.09% to $5.1 million in 2023, then jumped by 52.57% to $7.7 million in 2024, then climbed by 23.98% to $9.6 million in 2025.
• The last three Accumulated Depreciation figures came in at $9.6 million (Q2 2025), $8.6 million (Q1 2025), and $7.7 million (Q4 2024), per Business Quant data.